Advertisement

 

 

Omalizumab could be effective in children with severe eosinophilic non-allergic asthma.

Omalizumab could be effective in children with severe eosinophilic non-allergic asthma.
Author Information (click to view)

Bourgoin-Heck M, Amat F, Trouvé C, Bernard A, Magny JP, Lambert N, Just J,


Bourgoin-Heck M, Amat F, Trouvé C, Bernard A, Magny JP, Lambert N, Just J, (click to view)

Bourgoin-Heck M, Amat F, Trouvé C, Bernard A, Magny JP, Lambert N, Just J,

Advertisement

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2017 10 05() doi 10.1111/pai.12813
Abstract

Authors declare no relevant conflicts of interest related to the present work. Severe eosinophilic non-allergic asthma is a rare phenotype that could be effectively treated by omalizumab, especially when associated with elevated total serum IgE and nasal polyposis. Severe eosinophilic non-allergic asthma is a specific phenotype, rarely described in children, sometimes associated with nasal polyposis and aspirin intolerance (i.e., Widal’s syndrome). This asthma phenotype is known to be particularly severe and steroid resistant (1). This article is protected by copyright. All rights reserved.

Submit a Comment

Your email address will not be published. Required fields are marked *

fifteen − 1 =

[ HIDE/SHOW ]